Vemurafenib: all 121 studies that test it
Page 2 of 2. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.
- Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in MelanomaCompletedNCT01943422Phase 1
- An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic MelanomaCompletedNCT01898585Phase 4
- A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant MelanomaCompletedNCT01897116Phase 1
- Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus CobimetinibTerminatedNCT01876641Phase 1
- A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic MalignancyCompletedNCT01851824Phase 1
- A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic MalignancyCompletedNCT01849666Phase 1
- A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic MalignanciesCompletedNCT01844674Phase 1
- Radiation Use During Vemurafenib TreatmentWithdrawnNCT01843738Phase 1
- Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF MutationSuspendedNCT01841463Phase 1
- Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By SurgeryTerminatedNCT01835184Phase 1
- Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by SurgeryCompletedNCT01787500Phase 1
- A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer ParticipantsCompletedNCT01767623Phase 1
- A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic MelanomaWithdrawnNCT01765556Phase 1
- Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant GliomasCompletedNCT01748149Early Phase 1
- Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid CancerActive, not recruitingNCT01709292Phase 2
- A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced CancerCompletedNCT01673737Phase 1
- Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV MelanomaCompletedNCT01657591Phase 1
- Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.CompletedNCT01636908Not applicable
- Study of Vemurafenib, Carboplatin, and PaclitaxelCompletedNCT01636622Phase 1
- Leflunomide+Vemurafenib in V600 Mutant Met. MelanomaTerminatedNCT01611675Phase 1
- Vemurafenib and White Blood Cell Therapy for Advanced MelanomaTerminatedNCT01585415Phase 1